It is difficult to predict with certainty where Novo Nordisk will be in 10 years. However, based on their current trajectory and focus on innovation in pharmaceuticals and healthcare, it is likely that they will continue to be a leading global company in the industry, developing new treatments and technologies to improve the lives of patients worldwide.

Reported 6 months ago

Novo Nordisk has been a strong performer in the past decade, with a 527% return, largely attributed to its weight-loss drug Ozempic. However, with a more competitive weight-loss market emerging, the company's growth may slow down in the next 10 years despite its recent revenue and profit growth. While Novo Nordisk is still considered a good buy at its current price, investors should not expect the same high returns as in the past decade, but a doubling in stock value and reaching a market cap of $1 trillion is feasible.

Source: YAHOO

View details